Antimicrobial resistance (AMR) has a direct effect on patient care and patient outcomes. It increases the complexity of treatment and the duration of hospital stay, resulting in additional burden to patient. Clinicians and healthcare systems.
Australian Passive Antimicrobial Resistance Surveillance (APAS) is a key part of antimicrobial resistance (AMR) surveillance conducted through the AURA Surveillance System. APAS uses data collected passively from public and private pathology service Laboratory Information Systems (LISs) across Australia, and analyses and reports on this de-identified, patient level resistance data.
APAS provides the largest volume of resistance surveillance data to AURA. These data provide access to geographical and organism related trends in resistance and inform local, state and national AMR response strategies.